ArticleMolecular oncology2013
EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrol.
Article in Molecular oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Natural Modulators of Aquaporins in Cancer Therapy: Functional Mechanisms and Clinical Potential.Molecules (Basel, Switzerland) · 2026Review
- Characterization of the Signaling Pathways Activated by KCl-Induced RTK Stimulation in Guinea Pig Airways.Biology · 2025Article
- Plasma membrane SK2 channel activity regulates migration and chemosensitivity of high-grade serous ovarian cancer cells.Molecular oncology · 2024Article
- Effects of Resveratrol on In Vivo Ovarian Cancer Cells Implanted on the Chorioallantoic Membrane (CAM) of a Chicken Embryo Model.International journal of molecular sciences · 2024Article
- Advances in the role of resveratrol and its mechanism of action in common gynecological tumors.Frontiers in pharmacology · 2024Review
- Remodeling tumor microenvironment with natural products to overcome drug resistance.Frontiers in immunology · 2022Review
- Discoidin Domain Receptor 2 Mediates Lysophosphatidic Acid-Induced Ovarian Cancer Aggressiveness.International journal of molecular sciences · 2021Article
- Resveratrol Sensitizes Colorectal Cancer Cells to Cetuximab by Connexin 43 Upregulation-Induced Akt Inhibition.Frontiers in oncology · 2020Article
- Mechanisms of PAR-1 mediated kinase receptor transactivation: Smad linker region phosphorylation.Journal of cell communication and signaling · 2019Article
- Corrigendum to: EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: Inhibition by resveratrol.Molecular oncology · 2019Article
- Kinase-targeted cancer therapies: progress, challenges and future directions.Molecular cancer · 2018Review
- Lysophosphatidic Acid Receptor Antagonism Protects against Diabetic Nephropathy in a Type 2 Diabetic Model.Journal of the American Society of Nephrology : JASN · 2017Article
- Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis.Experimental & molecular medicine · 2017Article
- Epidermal growth factor promotes cyclin G2 degradation via calpain-mediated proteolysis in gynaecological cancer cells.PloS one · 2017Article
- Unraveling the Anticancer Effect of Curcumin and Resveratrol.Nutrients · 2016Review
- Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.Journal of lipid research · 2016Review
- Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780.Journal of Cancer · 2016Article
- High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer.OncoTargets and therapy · 2016Article
- Small lipidated anti-obesity compounds derived from neuromedin U.European journal of medicinal chemistry · 2015Article
- Resveratrol, Acetyl-Resveratrol, and Polydatin Exhibit Antigrowth Activity against 3D Cell Aggregates of the SKOV-3 and OVCAR-8 Ovarian Cancer Cell Lines.Obstetrics and gynecology international · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Lysophosphatidic acid (LPA) augments proliferation and metastasis of various cancer cells. We recently identified a critical role of the Rho/ROCK pathway for LPA-induced proteolytic enzyme expression and cancer cell progression. In the present study, we elucidate the underlying mechanisms by which LPA induces Rho activation and subsequent cellular invasion, and the reversal of these effects by resveratrol. We observed that both Gi and G13 contribute to LPA-induced EGFR activation. The activated EGFR in turn initiates a Ras/Rho/ROCK signaling cascade, leading to proteolytic enzyme secretion. Further we provide evidence that resveratrol inhibits EGFR phosphorylation and subsequent activation of a Ras/Rho/ROCK signaling. Therefore, we demonstrate a mechanistic cascade of LPA activating EGFR through Gi and G13 thus inducing a Ras/Rho/ROCK signaling for proteolytic enzyme expression and ovarian cancer cell invasion, as well as interference of the cascade by resveratrol through blocking EGFR phosphorylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.